This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shen, Y. Articles by Sarode, R Search for Related Content PubMed PubMed Citation Articles by Shen, Y. Articles by Sarode, R Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

IgA antiphospholipid antibodies are an independent risk factor for thromboses

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

R Lee

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

E Frenkel

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

R Sarode

Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA ravi.sarode{at}utsouthwestern.edu

Antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin and anti-β₂-glycoprotein I antibodies, mostly IgG isotype) are strong risk factors for thrombosis. Because a paucity of information on IgA isotype exists in the literature, we retrospectively evaluated the thrombotic significance of IgA antiphospholipid antibodies. We included 472 patients with clinical information on thrombotic events and complete laboratory work-up for antiphospholipid antibodies syndrome. Odds ratios (OR) of various antiphospholipid antibodies for thrombosis were calculated by univariate and multivariate analyses. Lupus anticoagulant alone was detected in 57 (12%) patients, ELISA-based antibodies (IgG, IgM, IgA) against cardiolipin, phosphatidylserine or β₂-glycoprotein-I alone were detected in 131 (28%) patients, whereas 80 (17%) patients had both. Antibody isotype distribution was IgG 32%, IgM 60% and IgA 56%. Univariate analysis showed a statistically significant risk of thrombosis in patients with elevated titres of IgA of any ELISA-based antiphospholipid antibodies (OR 1.77). Stepwise logistic regression (multivariate) analysis identified elevated titres of any ELISA-based IgA antiphospholipid antibodies as an independent risk factor for thrombosis (OR 1.6) in the entire cohort, and in the subgroup of patients without concurrent presence of lupus anticoagulant (OR 1.8). IgA antiphospholipid antibodies appear to be a significant independent risk factor for thrombosis, thereby meriting evaluation in patients with unexpected thrombosis.

Key Words: antiphospholipid antibodies • antiphospholipid syndrome • IgA • lupus anticoagulant

Lupus, Vol. 17, No. 11, 996-1003 (2008)
DOI: 10.1177/0961203308093460


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?